MedIntelliBase� Breaking News - Fenofibrate (Cardiovascular Therapies)

Genetics of hypertension and cardiovascular disease and their interconnected pathways: lessons from large studies.

Tue, 01 Feb 2011 04:00:00 GMT

Blood pressure (BP), hypertension (HT) and cardiovascular disease (CVD) are common complex phenotypes, which are affected by multiple genetic and environmental factors. This article describes

What combination therapy with a statin, if any, would you recommend?

Tue, 01 Feb 2011 04:00:00 GMT

The latest recommended goals for blood lipid levels may require multiple lipid drugs. Lower doses in combination may render more efficacy and safety than highest

Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.

Tue, 01 Feb 2011 04:00:00 GMT

Background and Aim: The treatment-of-choice for the optimal management of the dyslipidemia of the metabolic syndrome (MetS) is not clearly defined. We compared the efficacy

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Tue, 01 Feb 2011 04:00:00 GMT

AIMS/HYPOTHESIS: Fenofibrate caused an acute, sustained plasma creatinine increase in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk

Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.

Mon, 10 Jan 2011 04:00:00 GMT

We have previously reported that fenofibrate displayed a potent antithrombotic effect by the inhibition of platelet aggregation. The present study was designed to investigate the

'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.

Sat, 01 Jan 2011 04:00:00 GMT

Targeting elevations in low-density lipoprotein cholesterol (LDL-C) remains the cornerstone of cardiovascular prevention. However, this fraction does not adequately capture elevated triglyceride-rich lipoproteins (TRLs; e.g.

Refsum's Disease-Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder.

Sat, 01 Jan 2011 04:00:00 GMT

Refsum's Disease is an inherited metabolic disorder in which a metabolite of branched chain fatty acids accumulates due to lack of appropriate oxidative enzymes. Patients

Weight considerations in pharmacotherapy for type 2 diabetes.

Sat, 01 Jan 2011 04:00:00 GMT

Obesity has been increasing in prevalence worldwide and the majority of patients with type 2 diabetes are either overweight or obese. Diabetes management in this

Taking Orlistat: Predicting Weight Loss over 6 Months.

Sat, 01 Jan 2011 04:00:00 GMT

This study explored the predictors of weight loss following orlistat with a focus on both baseline variables and changes in beliefs and behaviours occurring over

Genetic loci associated with lipid concentrations and cardiovascular risk factors in the Korean population.

Sat, 01 Jan 2011 04:00:00 GMT

Background Dyslipidaemia, a key risk factor for cardiovascular disease (CVD), is strongly influenced by genetic factors. Objective To identify genetic factors affecting blood lipid concentrations

The influence of gene polymorphisms on coronary artery disease.

Sat, 01 Jan 2011 04:00:00 GMT

<< No Abstract Available >>

Vascular protective effects of ezetimibe: seeking new therapeutic possibilities of ezetimibe in vascular disease.

Sat, 01 Jan 2011 04:00:00 GMT

<< No Abstract Available >>

Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years.

Sat, 01 Jan 2011 04:00:00 GMT

Ezetimibe (EZE), a selective inhibitor of intestinal cholesterol absorption, is mostly used in combination with statins across various patient populations. Besides its low-density lipoprotein cholesterol

New concept of vascular calcification and metabolism.

Sat, 01 Jan 2011 04:00:00 GMT

Vascular calcification is recently considered as one of the major complications and an independent risk factor of cardiovascular diseases. Although vascular calcification was commonly regarded

Ezetimibe and vascular endothelial function.

Sat, 01 Jan 2011 04:00:00 GMT

Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de

Novel Role of NPC1L1 in the Regulation of Hepatic Metabolism: Potential Contribution of Ezetimibe in NAFLD/NASH Treatment.

Sat, 01 Jan 2011 04:00:00 GMT

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries and also in other parts of the world. NAFLD encompasses

Ezetimibe and reactive oxygen species.

Sat, 01 Jan 2011 04:00:00 GMT

Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor,

Ezetimibe and vascular inflammation.

Sat, 01 Jan 2011 04:00:00 GMT

Atherosclerosis is an inflammation-based complex vascular disorder which causes coronary artery disease, stroke and peripheral artery disease. Its pathophysiological process consists of endothelial dysfunction, monocyte

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.

Sat, 01 Jan 2011 04:00:00 GMT

Importance of the field: Dyslipoproteinaemia is a cardinal feature of the metabolic syndrome that accelerates atherosclerosis. It is usually characterized by high plasma concentrations of

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Sat, 01 Jan 2011 04:00:00 GMT

AIMS/HYPOTHESIS: We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering